Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almirall, a Spain-based pharma firm, has said the Spanish Ministry of Health has granted the reimbursement of Sativex in Spain.
Subscribe to our email newsletter
Sativex is an endocannabinoid system modulator made up principally of two active ingredients -THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol).
Sativex, administered as an oral spray, is specifically designed for patients with multiple sclerosis (MS)-related moderate to serious spasticity who have not adequately benefitted from other treatments.
The Phase III programme for Sativex in cancer pain started in late 2010.
Sativex was developed by GW Pharmaceuticals (UK) and Almirall holds marketing rights in Europe (except UK).
The approval of Sativex in additional EU member states is expected in 2011.